Latest Us Army News

EV Resources has reported impressive high-grade assays from its Milton Antimony Project in Nevada, revealing significant antimony, copper, and silver mineralisation and setting the stage for detailed follow-up exploration.

IperionX has boosted titanium powder production capacity by 60% and secured US$75 million in Department of War funding to scale up to 1,400 tonnes per annum by 2027, aiming to become the largest and lowest-cost US titanium producer.

Orbital Corporation Ltd reports a robust Q1 2025 with increased revenues, successful prototype completion of a new 350cc heavy fuel engine, and strategic partnerships positioning it for growth in the evolving UAV market.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

Resolution Minerals has begun a large-scale stream sediment sampling program at its Horse Heaven project in Idaho, aiming to uncover new critical mineral targets and validate geological links with Perpetua Resources’ adjacent Stibnite Gold Project.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

Pointerra Limited reported strong FY25 Q4 results marked by new enterprise customers, a major US defense subcontract, and significant cashflow improvements. The company’s AI-enhanced digital twin platform is gaining traction across multiple sectors, setting the stage for growth in FY26.

Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.

Li-S Energy has appointed Paladin Defense Services as its U.S. representative to accelerate engagement with the Department of Defense and defence contractors, aiming to commercialise its advanced battery technology in a critical market.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.